Overview
- Science Corp closed a $230 million Series C, bringing total funding to roughly $489–$490 million and drawing a reported valuation of $1.25 billion to $1.5 billion from media accounts.
- Backers in the round include Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT and Quiet Capital, according to the company.
- The company’s PRIMA system pairs a rice‑grain‑sized retinal implant with camera‑equipped glasses to help people with late‑stage macular degeneration interpret visual information.
- In trials across 47 patients in Europe and the U.S., about 80% showed meaningful visual acuity gains and could read letters, numbers and words, according to company‑reported results.
- Science says it has filed for a CE mark with expected EU approval around mid‑2026 and a likely first launch in Germany, is in ongoing FDA discussions, has acquired a North Carolina MEMS facility for in‑house production, and is expanding trials to Stargardt disease and retinitis pigmentosa while advancing biohybrid interface and organ‑preservation programs.